[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Taiwan University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":636},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,413,0,25,[9,46,72,99,132,152,176,199,221,247,272,298,328,356,376,393,413,430,448,473,498,527,553,577,605],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644606","pbm-patch-for-postoperative-pain-relief-after-urological-surgery-100644606",false,"NCT07671612","PBM Patch for Postoperative Pain Relief After Urological Surgery","A Double-blind Randomized Controlled Clinical Study of the PBM Patch for Postoperative Pain Relief After Urological Surgery","Inclusion Criteria:\n\n1. Patients aged 18 years or older undergoing unilateral nephroureterectomy with bladder cuff excision, or adrenalectomy (tumor size \\\u003C 3.5 cm).\n2. Patients who are capable of clear verbal communication.\n3. Patients who are able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Individuals with photosensitive constitution or those currently using photosensitizing medications.\n2. Individuals with a known history of severe allergy or contact dermatitis to medical adhesive patches or tapes.\n3. Patients with severe psychiatric illness or cognitive impairment.\n4. Long-term or high-dose opioid users.\n5. Patients utilizing a Patient-Controlled Analgesia (PCA) pump.\n6. Individuals with severe hepatic insufficiency or active liver disease.\n7. Vulnerable populations, individuals with restricted legal capacity, or those who are unable or unwilling to undergo clinical evaluations.","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a prospective, randomized, double-blind, placebo-controlled clinical study designed to evaluate the efficacy and safety of a photobiomodulation (PBM) patch (Super Vi PBM Patch - Soothing) and an enhanced PBM patch (Super Vi PBM Patch - Soothing EX), compared with a placebo patch, for postoperative pain relief following urological surgery, including nephroureterectomy with bladder cuff resection (NU+BCR) and adrenalectomy (ADRX).",[27,28,29,30,31],"Urological Surgery","Photobiomodulation (PBM)","Non-pharmacological Intervention","Double-blind Randomized Controlled Study","Postoperative Pain Relief",[31,28,27,30,29],"NOT_YET_RECRUITING","2026-06-25",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":21},"2026-07-01",{"date":41,"type":21},"2028-03-31",{"name":43,"class":44},"National Taiwan University Hospital","OTHER",2,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100645145","immersive-virtual-reality-training-for-stoma-care-100645145","NCT07677592","Immersive Virtual Reality Training for Stoma Care","The Effectiveness of Immersive Virtual Reality Training for Stoma Care on Nurses' Knowledge and Skill, Self-efficacy and Learning Satisfaction","IVRT_SC","Inclusion Criteria:\n\n* Full-time registered nurses employed at the study institution or nursing students currently enrolled in a formal nursing program\n* Willing to participate in the study and able to provide written informed consent\n\nExclusion Criteria:\n\n* Prior participation in virtual reality-based ostomy care training\n* Self-reported history of significant discomfort during VR use (e.g., dizziness, nausea, or other physical discomfort)\n* Individuals who consider themselves unable or unwilling to undergo VR training",true,{"count":56,"type":21},100,[24],"This study investigates the effectiveness of immersive virtual reality (VR) training in stoma care on nurses' knowledge, skills, self-efficacy, and learning satisfaction.\n\nUsing a mixed-method design with convenience sampling, 100 clinical nurses will be recruited and randomly assigned (1:1) to experimental and control groups. The experimental group will receive two VR training sessions one month apart, while the control group will attend a single traditional classroom session. Both groups will follow stoma care replacement procedures established by National Taiwan University Hospital.\n\nData collection will include demographic information, knowledge\u002Fskill tests, and self-efficacy questionnaires administered at three time points: before training, immediately after training, and one month post-training. Learning satisfaction will be assessed immediately after training. Participants reporting adverse VR reactions or scoring below 4 on satisfaction will be invited to one-on-one semi-structured interviews.",[60,61],"Stoma Care","Nursing Education",[63],"immersive virtual training program","2026-06-24",{"date":39,"type":37},{"date":67,"type":21},"2026-06-04",{"date":69,"type":21},"2028-12-31",{"name":43,"class":44},1,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":81,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100645029","hcc-risk-and-monitoring-in-patients-with-type-2-diabetes-100645029","NCT07675187","HCC Risk and Monitoring in Patients With Type 2 Diabetes","Hepatocellular Carcinoma Risk Assessment and Surveillance in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosed with type 2 diabetes mellitus and clinically followed with regular outpatient visits.\n* FIB-4 index greater than 2.67 (calculated based on AST, ALT, and platelet count within the past 6 months).\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* HBsAg positive.\n* Anti-HCV positive and HCV RNA positive (patients with anti-HCV positive but negative HCV RNA are still eligible).\n* Prior history of hepatobiliary malignancies.\n* Undergoing regular abdominal ultrasound screening more than once per year.\n* Established diagnosis of liver cirrhosis via abdominal ultrasound or clinical evaluation.\n* Diagnosed with or treated for any malignancy within the past 2 years.\n* Women of childbearing potential or pregnant women.\n* Thrombocytopenia secondary to hematologic disorders.\n* Known history of human immunodeficiency virus (HIV) infection.\n* Concomitant use of medications that may interfere with PIVKA-II assay results (e.g., warfarin, vitamin K).",{"count":80,"type":21},2400,"3 Years","OBSERVATIONAL","Liver cancer is a significant malignancy in Taiwan. With the widespread implementation of antiviral therapies, hepatitis B and C-related liver cancer has gradually declined; however, metabolic dysfunction-associated liver cancer continues to increase, particularly among patients with type 2 diabetes mellitus (T2DM) who also present with significant liver fibrosis. Current clinical guidelines lack standardized recommendations for liver cancer screening in this specific population, and data from prospective randomized controlled trials remain scarce.This study is a prospective randomized controlled trial enrolling patients aged 18 years, diagnosed with T2DM, and with a FIB-4 \\> 2.67. Participants will be randomly assigned to either the surveillance group or the standard-care group. The surveillance group will undergo blood tests every 6 months to monitor liver function, AFP, and PIVKA-II, alongside the calculation of the GAAD score. The standard-care group will receive liver function tests every 6 months according to routine clinical practice. Abdominal ultrasound or computed tomography (CT) scans will be arranged by clinicians when clinically indicated. All participants will undergo abdominal ultrasound at baseline and at the end of the third year, with blood samples and clinical data collected periodically. The primary endpoint of this study is the tumor size at the time of liver cancer diagnosis. Secondary endpoints include liver cancer staging, number of liver cancer tumors, liver cancer incidence, the proportion of patients receiving curative treatment, and the degree of liver fibrosis as reflected by changes in FIB-4. This study expects to clarify the clinical benefits of a GAAD score-based surveillance strategy compared to standard care in T2DM patients with high FIB-4 scores, thereby providing evidence-based support for future liver cancer screening strategies and clinical guidelines.",[85,86],"Type 2 Diabetes (T2DM)","Hepatocellular Carcinoma (HCC)",[88,89,90,91],"Type 2 Diabetes","Liver Cancer","Surveillance","Prospective Randomized Study","2026-06-23",{"date":94,"type":37},"2026-06-30",{"date":39,"type":21},{"date":97,"type":21},"2030-12-31",{"name":43,"class":44},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":71},"100588188","phase-4-effects-of-cycle-therapy-vs-sequential-therapy-with-romosozumab-and-denosumab-in-postmenopausal-osteoporosis-patients-100588188","NCT06938152","Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients","Effects of Cycle Therapy With Romosozumab and Denosumab 2 Years vs 1 Year Romosozumab Followed by 1 Year Denosumab in Postmenopausal Osteoporosis Patients-A Randomized Control Trial","Inclusion Criteria:\n\n* 1\\. Postmenopausal women aged 50-90 years\n* 2\\. BMD T-score ≤ -3.0 at any lumbar vertebra\n* 3\\. Physically and mentally capable of understanding and complying with the study protocol and follow-up\n* 4\\. Signed informed consent\n\nExclusion Criteria:\n\n* 1\\. Previous osteoporosis treatment within the past two years, including Romosozumab, Teriparatide, Denosumab, Alendronate, Ibandronate, Zoledronic Acid, Risedronate, Raloxifene, or Bazedoxifene\n* 2\\. Allergy to Romosozumab or Denosumab\n* 3\\. Secondary osteoporosis\n* 4\\. Autoimmune disease\n* 5\\. Chronic steroid use (e.g., Chronic Obstruction Pulmonary Disease patients)\n* 6\\. Hypercalcemia or hypocalcemia\n* 7\\. Metabolic bone diseases\n* 8\\. Primary or metastatic bone tumors\n* 9\\. Cancer patients (except for in situ carcinoma and non-melanoma skin cancer, unless fully treated and in remission for five years)\n* 10\\. Planned dental procedures (e.g., extractions, implants) within the next year\n* 11\\. History of stent placement, myocardial infarction, stroke, or coronary artery disease\n* 12\\. Renal disease (Creatinine \\> 1.5 mg\u002FdL) or dialysis patients\n* 13\\. Smoking more than one pack per day (except for those who have quit for over ten years)","FEMALE","50 Years","90 Years",{"count":110,"type":21},70,[112],"PHASE4","This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a traditional sequential treatment regimen (12 months of Romosozumab followed by 12 months of Denosumab). The goal is to determine which approach yields better therapeutic outcomes and to optimize drug strategies for osteoporosis patients.",[115,116],"Osteoporosis","Osteoporosis Postmenopausal",[118,119,120,121,122,123],"postmenopausal","Romosozumab","Denosumab","cycle therapy","Bone mineral density","Bone turnover marker","RECRUITING","2026-06-21",{"date":92,"type":37},{"date":128,"type":37},"2025-04-08",{"date":130,"type":21},"2029-12-31",{"name":43,"class":44},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":17,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":151,"locationsCount":71},"100497880","application-of-artificial-intelligence-on-the-diagnosis-of-helicobacter-pylori-infection-and-premalignant-gastric-lesion-100497880","NCT05762991","Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion","Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age 20-80\n2. Scheduled endoscopy\n\nExclusion Criteria:\n\n1\\. History of gastric surgery","20 Years","80 Years",{"count":142,"type":21},6000,"The aim of this study is to evaluate the impact of artificial intelligence (AI) assistance during routine upper endoscopy on gastric cancer-specific mortality. We hypothesize that AI-assisted endoscopic interpretation can further reduce gastric cancer-related mortality through two mechanisms: (1) improved detection of H. pylori infection, facilitating timely eradication therapy and subsequent prevention of gastric carcinogenesis; and (2) earlier identification of premalignant gastric conditions, enabling appropriate surveillance endoscopy and earlier detection of gastric cancer. The primary endpoint is gastric cancer-specific mortality.",[145,146],"Helicobacter Pylori Infection","Premalignant Lesion",{"date":64,"type":37},{"date":149,"type":37},"2021-12-24",{"date":69,"type":21},{"name":43,"class":44},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":71},"100549615","the-impact-of-continuous-glucose-monitoring-on-maternal-and-infants-outcomes-in-gestational-diabetes-100549615","NCT06436326","The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes","The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes: Testing the Moderating Effects of Socioeconomic and Cultural Factors","Inclusion Criteria:\n\n* Aged 18 years or above\n* Pregnant women diagnosed with gestational diabetes mellitus\n* Those who are willing to participate in this study\n\nExclusion Criteria:\n\n* Those who have been diagnosed with diabetes mellitus \"before pregnancy\"\n* Those whose skin is likely allergic to some materials such as tapes (signs and symptoms such as redness, swelling, itching, painful, presenting blisters or rashes caused by wearing breathable tapes, patches, etc.)\n* Those who is with abnormal coagulation function",{"count":160,"type":21},120,[24],"This study will discuss the impact of continuous glucose monitoring on maternal and infant's outcomes in gestational diabetes mellitus, and test the moderating effect of socioeconomic and cultural factors (dietary habits, socioeconomic status and income).",[164,165],"Gestational Diabetes Mellitus","Continuous Glucose Monitoring",[164,165,167],"Health Interventions","2026-06-17",{"date":170,"type":37},"2026-06-22",{"date":172,"type":37},"2024-08-22",{"date":174,"type":21},"2027-12-31",{"name":43,"class":44},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":71},"100642047","peer-learning-versus-physician-led-pocus-training-for-nurse-practitioners-in-integrative-volume-status-assessment-100642047","NCT07660016","Peer-Learning Versus Physician-Led POCUS Training for Nurse Practitioners in Integrative Volume Status Assessment","Feasibility of a Peer-Learning Ultrasound Program to Enhance Nurse Practitioners' Competence in Integrative Volume Status Assessment","Inclusion Criteria:\n\nParticipants aged 18 years or older. Licensed nurse practitioners or nurse practitioner trainees currently enrolled in an accredited nurse practitioner training program.\n\nAble to understand the study procedures and provide written informed consent. Able to participate in the complete training program and study assessments, including baseline, post-training, and 1-month follow-up assessments.\n\nNo prior formal POCUS training, or only limited basic exposure without systematic training experience.\n\nExclusion Criteria:\n\nParticipants who have previously completed a formal point-of-care ultrasound training program.\n\nParticipants who are unable to complete the full training program or study assessment procedures.\n\n\\-","99 Years",{"count":185,"type":21},60,[24],"This study aims to develop and evaluate a peer-led training program specifically designed for Nurse Practitioners (NPs) to acquire Point-of-Care Ultrasound (POCUS) skills. POCUS, known for its non-invasive nature and real-time imaging capability, has been widely applied in clinical fluid status assessment and plays a pivotal role in enhancing diagnostic efficiency and quality of care. However, current POCUS training resources for NPs in Taiwan remain insufficient, limiting their clinical application and professional visibility. Using a quasi-experimental design, this study investigates the effectiveness of peer-led instruction in strengthening image interpretation, clinical reasoning, and self-efficacy among NPs. The ultimate goal is to establish an evidence-based, nursing-oriented POCUS education model to fill existing gaps in the training system and elevate the role of NPs in multidisciplinary care.",[189],"Physician-led Versus Peer NP-led POCUS Training",[191],"POCUS, peer learning, NP","2026-06-16",{"date":170,"type":37},{"date":195,"type":21},"2026-08-02",{"date":197,"type":21},"2026-11-30",{"name":43,"class":44},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":17,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":71},"100568178","exploring-the-gut-brain-behavior-axis-with-biomarkers-probiotic-efficacy-and-artificial-intelligence-algorithms-100568178","NCT06677840","Exploring the Gut-Brain-Behavior Axis With Biomarkers, Probiotic Efficacy, and Artificial Intelligence Algorithms","Precision Health in Autism: Exploring the Gut-Brain-Behavior Axis With Biomarkers, Probiotic Efficacy, and Artificial Intelligence Algorithms","Inclusion Criteria:\n\n* Children and adolescents aged 4 to 15 who are clinically diagnosed with ASD according to DSM-5 criteria and confirmed by the ADI-R\u002FADOS.\n* Caregivers cooperate with all the assessments and stool and blood collection.\n\nExclusion Criteria:\n\n* A history of major psychiatric disorders (e.g., schizophrenia, bipolar disorder, major depression), neurological disorders, and substances use disorders.\n* Difficulty following instructions.\n* Consumption of antibiotics and yogurt or probiotic products two weeks prior to enrollment.","4 Years","15 Years",{"count":209,"type":21},110,[24],"This groundbreaking human study on the ASD microbiome includes probiotic clinical trials, investigation of treatment biomarkers, machine learning\u002Fdeep learning platform development for ASD classification and prediction, and identification of diagnostic biomarkers. Upon completion, the investigators anticipate publishing at least 12 SCI papers and\u002For patents and establishing an auxiliary diagnosis platform for both clinical and academic purposes. The findings will offer new insights into the pathogenetic mechanisms, improving early detection, diagnosis, and treatment, ultimately advancing precision medicine for ASD.",[213],"Autism Spectrum Disorder",{"date":215,"type":37},"2026-06-18",{"date":217,"type":37},"2024-05-01",{"date":219,"type":21},"2028-04-30",{"name":43,"class":44},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":54,"sex":17,"minAge":139,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":246,"locationsCount":71},"100641358","the-impact-of-shoulder-immobilization-by-orthoses-on-human-joint-biomechanics-and-inter-joint-coordination-100641358","NCT07659054","The Impact of Shoulder Immobilization by Orthoses on Human Joint Biomechanics and Inter-joint Coordination","Biomechanics","Inclusion Criteria:\n\n* Patients with mid-shaft clavicle fractures aged between 20-65 years old. Free from any neuromusculoskeletal disease of the lower limbs and the lower back except for the clavicle fractures\n* Patients with acute shoulder rotators severe rupture aged between 20-65 years old. Free from any neuromusculoskeletal disease of the lower limbs and the lower back except for the shoulder rotators rupture.\n* Healthy controls with age, height, and weight matched to patient groups. Free from any neuromusculoskeletal disease of the lower limbs and the lower back.\n\nExclusion Criteria:\n\n* Individuals who have other gait altering disorders.\n* Age below 20 or above 65.\n* If a female participant is pregnant, she will be excluded until recovery from pregnancy.\n* If he\u002Fshe rejects to give his\u002Fher informed consent.\n* Has any neuromusculoskeletal diseases, orthopedic or medical diseases other than shoulder injuries resulting in difficulty of motion and ambulation.","65 Years",{"count":230,"type":21},30,[24],"Shoulder joint orthoses are commonly used for patients with shoulder disorders to stabilize and protect shoulder joint after injury or surgery. These devices maintain proper anatomical alignment of the shoulder joint and surrounding soft tissues, reducing pain, facilitating proper recovery, and preventing further injury. Commonly used shoulder orthoses include shoulder sling, abduction brace, and figure-of-eight shoulder brace. The appropriate orthosis is selected based on patient's specific clinical needs, and it should be worn for an appropriate duration to avoid over or inadequate shoulder immobilization.\n\nWhen patients wear shoulder orthoses during daily activities, such as sit-to-stand, level walking, climbing stairs, or overcoming obstacles of a certain height, the immobilized shoulder reduces reciprocal arm swing, altering body's balance mechanism and potentially increasing the risk of falls. Different shoulder orthoses with various shoulder position affect human motor coordination and balance to varying degrees. Therefore, assessing the changes in body movements caused by shoulder immobilization with orthoses can provide crucial clinical information to aid in clinical decision-making.\n\nThis study utilizes stereophotogrammetry to measure and analyze subjects' motion changes while their shoulders are immobilized with orthoses. It aims to understand the biomechanical changes when subjects participate in static balance tests and dynamic activities. Through corresponding biomechanical analyses, including kinematics, dynamics, and joint coordination, the study seeks to understand the extent of the impact of shoulder orthoses on human movements. This information would serve as important reference data for subsequent clinical decisions regarding whether to use orthoses or not, the duration of use, and the suitability of the orthoses for patients of different ages.",[234,235],"Motion Analysis","Biomechanical Parameters",[237,238,239,240],"Motion analysis","stereophotogrammetry","Biomechanical analysis","Joint coordination","2026-06-15",{"date":170,"type":37},{"date":244,"type":37},"2024-11-27",{"date":97,"type":21},{"name":43,"class":44},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":271,"locationsCount":71},"100642677","phase-4-the-clinical-outcomes-and-therapeutic-effects-in-patients-with-cardiac-implantable-electronic-device-detected-subclinical-and-clinical-atrial-fibrillation-100642677","NCT07649109","The Clinical Outcomes and Therapeutic Effects in Patients With Cardiac Implantable Electronic Device-detected Subclinical and Clinical Atrial Fibrillation.","National Tawan University Hospital","AHRE","Inclusion Criteria Age ≥18 years. Presence of a cardiac implantable electronic device (CIED), including permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device.\n\nDevice-detected atrial high-rate episodes (AHREs) lasting ≥6 minutes and \\\u003C24 hours.\n\nAbility to provide written informed consent. Willingness and ability to comply with study procedures and follow-up visits. Exclusion Criteria Prior diagnosis of clinical atrial fibrillation, atrial flutter, or atrial tachycardia requiring treatment.\n\nDevice-detected AHRE ≥24 hours before enrollment. Current treatment with class I or class III antiarrhythmic drugs for atrial arrhythmias.\n\nPrevious catheter ablation for atrial fibrillation or atrial flutter. Planned catheter ablation within the next 3 months. Contraindication to rhythm-control therapy as determined by the treating physician.\n\nLife expectancy less than 1 year. Severe comorbid illness that may interfere with study participation or follow-up.\n\nPregnancy or breastfeeding. Participation in another interventional clinical trial that may affect study outcomes.",{"count":256,"type":21},450,[112],"Atrial high-rate episodes (AHREs) detected by cardiac implantable electronic devices (CIEDs) are associated with an increased risk of progression to clinical atrial fibrillation (AF), stroke, heart failure, and mortality. However, optimal management strategies for patients with AHREs lasting between 6 minutes and 24 hours remain uncertain. Current guidelines recommend risk factor modification, but the role of early rhythm-control therapy in preventing AHRE progression has not been well established.\n\nThis prospective, randomized, open-label study aims to evaluate whether a rhythm-control strategy combined with optimal risk factor management can reduce progression to sustained AHREs (≥24 hours) or clinical AF compared with optimal risk factor management alone in patients with device-detected AHREs. Eligible participants with CIED-detected AHREs lasting 6 minutes to 24 hours and without prior clinical AF will be randomly assigned to either a rhythm-control group or a usual-care group. The primary endpoint is progression to AHRE duration ≥24 hours or documented clinical AF. Secondary endpoints include stroke, systemic embolism, heart failure hospitalization, cardiovascular death, and all-cause mortality.",[260,261],"Subclinical Atrial Fibrillation","Cardiac Arrhythmias",[263,264,265],"Atrial High-Rate Episodes (AHRE)","Cardiac Implantable Electronic Device","Early Rhythm Control","2026-06-11",{"date":192,"type":37},{"date":269,"type":37},"2025-10-01",{"date":174,"type":21},{"name":43,"class":44},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":286,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":45},"100587955","feasibility-of-tracheobronchial-defect-reconstruction-using-allogenic-aortic-patch-100587955","NCT06935110","Feasibility of Tracheobronchial Defect Reconstruction Using Allogenic Aortic Patch","Inclusion Criteria:\n\n1. Congenital tracheal deformities: Includes congenital tracheomalacia, congenital tracheobronchial malformations, complete tracheal rings, etc., with severe clinical symptoms and cases where treatment is recommended after evaluation.\n2. Acquired tracheal stenosis: Includes tracheal narrowing caused by diseases, endotracheal intubation, or postoperative scar tissue, with severe clinical symptoms and cases where treatment is recommended after evaluation.\n3. Tracheal injury or tissue defect caused by trauma or burns: Cases requiring surgical repair.\n4. Tracheal tumors: Reconstruction of tracheal tissue following the removal of benign or malignant tumors.\n\nExclusion Criteria:\n\n1. Patients who are unable to provide informed consent.\n2. Pulmonary tumors that can be treated with standard lobectomy.\n3. Locally invasive tumors that are unresectable.\n4. Presence of contralateral lymph node metastasis.\n5. Presence of distant metastasis, except for solitary, resectable brain metastasis.\n6. Tracheal lesions amenable to standard resection with direct anastomosis.\n7. Preoperative evaluation indicates inability to undergo standard lobectomy.\n8. Patients infected with human immunodeficiency virus (HIV) or with other immunodeficiency disorders.\n9. Any condition or circumstance deemed by the principal investigator to potentially interfere with the conduct of the trial (e.g., severely impaired cardiopulmonary function, significant liver or kidney dysfunction, poorly controlled diabetes, high-risk groups, or pregnancy).\n10. Individuals with concerns about the potential risks of the trial.",{"count":279,"type":21},10,[24],"The investigators investigate the feasibility and safety of using cryopreserved aortic patches for tracheal or bronchial defect repair.",[283,284,285],"Trachea Diseases","Airway Remodeling","Reconstruction Surgery",[287,288,289,290],"cryopreserved aortic patch","airway repair","tracheal reconstruction","bronchial reconstruction",{"date":292,"type":37},"2026-06-12",{"date":294,"type":37},"2025-09-15",{"date":296,"type":21},"2029-10",{"name":43,"class":44},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":314,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":325,"leadSponsor":327,"locationsCount":71},"100622315","tirzepatide-to-reduce-recurrence-and-burden-after-ablation-of-atrial-fibrillation-100622315","NCT07382024","Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation","Tirzepatide to Reduce Recurrence and Burden After Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Trial","TREAT-AF","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Diagnosed with persistent atrial fibrillation and scheduled for de novo catheter ablation.\n3. Body mass index (BMI) ≥27 kg\u002Fm² at screening accompanied by at least one weight-related comorbidity (including cardiovascular disease, hypertension, dyslipidemia, or prediabetes).\n4. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Long-standing AF or marked left atrial enlargement (persistent AF duration \\> 5 years or left atrial anterior-posterior diameter \\> 50 mm).\n2. AF secondary to reversible causes (e.g., hyperthyroidism, acute infection, acute pulmonary embolism, recent cardiac surgery).\n3. Severe structural heart disease that may significantly affect ablation outcomes (e.g., hypertrophic cardiomyopathy, rheumatic valvular disease, dilated cardiomyopathy).\n4. Planned major non-AF-related surgery or interventional procedure within 3 months.\n5. Other arrhythmias requiring chronic antiarrhythmic drug therapy.\n6. Intracardiac thrombus or any contraindication to catheter ablation as judged by the investigator.\n7. Active systemic infection at screening.\n8. Contraindications to tirzepatide or GLP-1\u002FGIP receptor agonists (e.g., prior serious hypersensitivity, personal or family history of medullary thyroid carcinoma or MEN2, history of clinically significant pancreatitis, severe gastrointestinal disease that may impair tolerance or absorption).\n9. Poorly controlled type 1 diabetes, recent diabetic ketoacidosis, end-stage renal disease requiring dialysis, or severe hepatic dysfunction judged clinically significant.\n10. Pregnancy, breastfeeding, or women of childbearing potential unwilling or unable to use adequate contraception during the study.\n11. Participation in another interventional clinical study within 30 days prior to screening or planned participation during the study period.\n12. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation, including inability to comply with study procedures or follow-up.",{"count":307,"type":21},200,[24],"The goal of this clinical trial is to determine whether tirzepatide can reduce atrial fibrillation (AF) burden after catheter ablation in overweight or obese patients with persistent AF. It will also evaluate the effects of tirzepatide on body weight, metabolic risk factors, and clinical outcomes, as well as its safety and tolerability in this population.\n\nThe main questions it aims to answer are:\n\n1. Does peri-procedural treatment with tirzepatide reduce AF burden at 3 months after de novo catheter ablation, as measured by 7-day continuous ECG patch monitoring?\n2. Does tirzepatide lead to greater weight loss and improvement in metabolic parameters compared with standard care alone?\n3. Does tirzepatide reduce AF recurrence and cardiovascular events during 12 months of follow-up? Researchers will conduct a multi-center, open-label, endpoint-blinded, randomized controlled trial in adults aged 18-80 years with persistent AF and body mass index ≥25 kg\u002Fm² who are scheduled for de novo catheter ablation. Participants will be randomized 1:1 to receive either tirzepatide plus standard peri-procedural and post-ablation care or standard care alone.\n\nParticipants in the tirzepatide group will receive subcutaneous tirzepatide 2.5 mg once weekly starting about 4 weeks before ablation and continuing for 3 months afterward, for a total treatment duration of approximately 4 months. All participants will be followed at 1, 2, 3, 6, and 12 months after ablation, with detailed assessment of AF burden, AF recurrence, echocardiographic parameters, metabolic profile, quality of life by the AFEQT questionnaire, and safety events.",[311,312,313],"Atrial Fibrillation Ablation","Persistent Atrial Fibrillation","Obesity & Overweight",[315,316,317,318,319,320,321],"Atrial fibrillation","Catheter ablation","Tirzepatide","Overweight and obesity","AF burden","Recurrence","Quality of life","2026-06-10",{"date":292,"type":37},{"date":192,"type":21},{"date":326,"type":21},"2028-07-31",{"name":43,"class":44},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":17,"minAge":139,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":354,"leadSponsor":355,"locationsCount":71},"100643729","a-feasibility-study-of-ai-assisted-physiotherapy-for-oral-cancer-patients-100643729","NCT07635381","A Feasibility Study of AI-Assisted Physiotherapy for Oral Cancer Patients","A Feasibility Study of AI-Assisted Physiotherapy for Oromandibular and Neck-Shoulder Mobility in Oral Cancer Patients","Inclusion Criteria:\n\n* Oral cancer patients with trismus, clinical signs of neck or shoulder joint impairment after oral cancer surgery or radiotherapy in recent 12 months\n* Age between 20 and 70 years\n\nExclusion Criteria:\n\n* Could not communicate\n* Had any disorder that could influence movement performance (e.g., stroke, Parkinsonism, head injury)","70 Years",{"count":337,"type":21},15,[24],"This study aims to evaluate the feasibility, safety, and acceptability of a newly developed artificial intelligence (AI)-assisted physiotherapy system for oromandibular and neck-shoulder range of motion (ROM) in patients who have undergone treatment for oral cancer.\n\nIn this single-group, prospective, non-randomized pilot study, recruited participants will receive 4 to 6 weeks of AI-assisted physiotherapy. Participants will undergo a comprehensive clinical evaluation at baseline and post-intervention. During the intervention period, the AI system will perform a daily automated assessment to dynamically generate and adjust personalized exercise programs. Participants will perform these prescribed programs 4 to 6 times daily. Pre- and post-intervention changes, along with key feasibility parameters, acceptability, and safety metrics, will be statistically analyzed to inform future definitive trials.",[341,342],"AI (Artificial Intelligence)","Oral Cancer",[344,345,346,347,348,349],"Oral cancer","Artificial intelligence","Maximum interincisal opening","Physiotherapy","Range of motion","Neck and shoulder","2026-06-08",{"date":352,"type":37},"2026-06-09",{"date":241,"type":21},{"date":174,"type":21},{"name":43,"class":44},{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":22,"phases":364,"briefSummary":365,"conditions":366,"keywords":368,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":375,"locationsCount":4},"100642630","immunogenicity-of-mf59-adjuvanted-versus-high-dose-influenza-vaccine-in-people-with-hiv-a-randomized-clinical-trial-100642630","NCT07644546","Immunogenicity of MF59-adjuvanted Versus High-dose Influenza Vaccine in People With HIV: a Randomized Clinical Trial","Inclusion Criteria:\n\n* PWH aged ≥18 years\n\nExclusion Criteria:\n\n* History of confirmed severe adverse effects owing to any type of influenza vaccine, including anaphylaxis and Guillain-Barré syndrome.\n* Severe coagulopathy which causes contraindication for vaccination.\n* Already vaccinated with any type of 2026-2027 influenza vaccines.\n* Having diagnosed with influenza one month before vaccination.",{"count":363,"type":21},350,[24],"Seasonal influenza causes morbidity in people with impaired immunity, including adults with elder ages and other comorbidities \\[1\\]. Standard-dose inactivated influenza vaccines (IIV) may induce lower hemagglutination inhibition (HAI) titers and more rapid waning in these groups. High-dose IIV could generate higher and more durable serological responses, including HAI, B-cell activation and antibody magnitude, which was demonstrated in randomized trials \\[2,3\\]. MF59-adjuvanted IIV further enhances innate immune activation and antigen presentation, potentially broadening and strengthening responses, particularly during antigenic drift seasons \\[4\\]. These enhanced platforms represent biologically distinct strategies to overcome reduced vaccine responsiveness.\n\nInfluenza A\u002FH3N2 was reported as the predominant circulating strain in Taiwan. Initial antigenic characterization suggested suboptimal match between some circulating A\u002FH3N2 viruses (the subclade K variant) and the vaccine reference strain, whereas A\u002FH1N1 viruses appeared consistency with the circulating and vaccine-containing strain \\[5\\]. As of February 2026, approximately 2,300 cases of severe influenza had been confirmed during the 2025-2026 season, representing the largest epidemic in the post-COVID-19 era. In the meanwhile, both MF59-adjuvanted and high-dose influenza vaccine were firstly introduced in Taiwan for elderly people \\[5\\].\n\nPrevious study had demonstrated that people living HIV (PWH) might have lower humoral immune responses compared with people without HIV, even among PWH with relatively higher (defined as ≥ 350 cells\u002Fmm3) CD4 counts \\[6\\]. In spite of the broad use of these novel influenza vaccines in older adults and other population with immunocompromised status such as the recipient of solid organ transplantation \\[7\\], evidence gap exists in PWH, where vaccine responses vary by CD4 count, viral suppression, immune activation, comorbidities, and prior vaccination history. High-dose influenza vaccination has shown improved serologic outcomes versus standard dose in PWH in randomized trials \\[2\\], while data of MF59-adjuvanted vaccines used for PWH are lacking. Moreover, comparative serological responses, durability or effectiveness between the two vaccines (MF59 adjuvant vs high-dose) was only conducted among participants with elder age, which showed that the seroconversion rate for H3N2 among those receiving MF59-adjuvanted vaccines did not meet noninferiority criteria compared with those receiving high-dose vaccines \\[8\\]. Nevertheless, such data on PWH remains unclear. In this study, we aimed to compare toe immunogenicity among PWH undergoing MF59-adjuvanted or high-dose seasonal influenza vaccine.",[367],"HIV",[367,369,370],"influenza","vaccine",{"date":292,"type":37},{"date":373,"type":21},"2026-09-01",{"date":69,"type":21},{"name":43,"class":44},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":392,"locationsCount":71},"100632490","phase-4-the-effect-of-rifabutin-in-mycobacterium-abscessus-with-inducible-clarithromycin-resistance-100632490","NCT07514364","The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance","The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance: a Randomized Study","Inclusion Criteria:\n\n* Adults aged ≥ 18 years\n* Diagnosis of pulmonary disease caused by Mycobacterium abscessus confirmed by clinical evaluation and laboratory results\n* Antimicrobial susceptibility testing indicating inducible resistance to clarithromycin\n* Clinically stable and suitable for antibiotic treatment\n* Radiographic evidence of active pulmonary infection\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Known hypersensitivity to rifabutin or intolerance to other study medications\n* Pregnant or breastfeeding women",{"count":185,"type":21},[112],"Background: Mycobacterium abscessus, one of the most common species of nontuberculous mycobacterium (NTM), poses a significant clinical challenge due to its natural resistance to antibiotics and high treatment failure rates, particularly in lung diseases. Among its subspecies, M. abscessus subspecies abscessus is especially prone to developing inducible resistance to Clarithromycin. This resistance mechanism is primarily due to the activation of the erm(41) gene,which inhibits Clarithromycin from effectively binding to the bacterial ribosome, diminishing its bactericidal efficacy. Rifabutin, an antibiotic widely used in treating tuberculosis and certain NTM infections, has been shown to inhibit the activation of the erm(41) gene by suppressing the whiB7 protein in M. abscessus, suggesting potential efficacy against inducible resistance. However,current evidence primarily stems from in vitro susceptibility studies and case reports, with a notable lack of systematic clinical trials.",[387],"Mycobacterium Abscessus Lung Disease",{"date":322,"type":37},{"date":390,"type":37},"2026-01-01",{"date":215,"type":21},{"name":43,"class":44},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":399,"maxAge":400,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":412,"locationsCount":71},"100566944","clinic-based-and-technology-supported-sleep-intervention-for-pediatric-epilepsy-100566944","NCT06661759","Clinic-based and Technology-Supported Sleep Intervention for Pediatric Epilepsy","Inclusion Criteria:\n\n* Children aged between 1.5 and 9 years with a confirmed diagnosis of epilepsy.\n* Parents with sufficient Chinese language skills to fully comprehend the trial and complete questionnaires.\n\nExclusion Criteria:\n\n* Children who are bedridden.\n* Children with a documented sleep disorder, such as obstructive or central sleep apnea and sleep-related movement disorders\n* Children born with a congenital, genetic, or orthopedic abnormality that limit their activities of daily living or impair their physical activity.","18 Months","9 Years",{"count":402,"type":21},150,[24],"Sleep problems are more common and more severe in children with epilepsy. The purpose of this study is to develop and evaluate the effect of a clinic-based and technology-supported sleep intervention for improving sleep and health in children with epilepsy and their parents.",[406],"Epilepsy","2026-06-07",{"date":322,"type":37},{"date":410,"type":37},"2024-11-19",{"date":174,"type":21},{"name":43,"class":44},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":54,"sex":17,"minAge":139,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":71},"100491364","validation-of-soluble-programmed-death-1-in-predicting-progression-of-nodular-bronchiectatic-form-of-nontuberculous-mycobacterial-lung-disease-a-multi-country-research-100491364","NCT05678166","Validation of Soluble Programmed Death-1 in Predicting Progression of Nodular-bronchiectatic Form of Nontuberculous Mycobacterial Lung Disease: a Multi-Country Research","Inclusion Criteria:\n\n* Age ≥ 20 years\n* NTM-LD: (N=250) Diagnosis is made on the basis of the guidelines produced by the American Thoracic Society.Patients have pulmonary symptoms with identified chest image and fit with the microbiology criteria.\n* NTM pulmonary colonizers and others: (N=100) Those without fulfilling the diagnostic criteria but having at least one set of positive sputum for MAC or patients infected with NTM other than MAC species.\n* Pulmonary tuberculosis (TB): (N=100) Those with respiratory specimen culture positive for Mycobacterium tuberculosis or typical TB pulmonary pathology.\n* Healthy control (N=50)\n\nExclusion Criteria:\n\n* Patients who have acquired immunodeficiency syndrome",{"count":420,"type":21},500,"The incidence of nontuberculous mycobacterial lung disease (NTM-LD) is increasing worldwide and in Eastern Asia. NTM-LD leads significant morbidity and mortality, around 25% within 5 years, but the treatment rate is low because the course of NTM-LD is indolent, especially in nodular-bronchiectatic (NB) form. However, there is no biomarker proven for predicting the progression in NB form of NTM-LD. Recently, it has been reported that the ratio of membrane-form programmed death-1 (PD-1) expressed T cells increased in patients with NTM-LD and it was associated with disease severity and progression. The mechanism has been speculated as a \"immune exhaustion\". In contrast to PD-1 expressed in cell membrane, soluble-form PD-1 is another biomarker that can be easily detected in serum. We recently reported that soluble PD-1 significantly correlated with cavitary lesion and disease progression in patients with NB-form NTM-LD in Taiwan. However, this has not been validated in other countries and ethnicities. Furthermore, the usefulness of soluble PD-1 in diagnosis and predicting mortality warrants further studies.",[423],"Nontuberculous Mycobacterial Lung Disease",{"date":322,"type":37},{"date":426,"type":37},"2023-01-31",{"date":428,"type":21},"2026-12-31",{"name":43,"class":44},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":446,"leadSponsor":447,"locationsCount":71},"100642863","artificial-intelligence-based-dietary-care-system-100642863","NCT07637565","Artificial Intelligence-based Dietary Care System","Effectiveness of An Artificial Intelligence-based Dietary Care System for Distress From Altered Bowel Function and Quality of Life in Rectal Cancer Patients With Low Anterior Resection Syndrome","AI DC-system","Inclusion Criteria:\n\n* Age ≥18 years.\n* Clear consciousness with ability to communicate in Mandarin or Taiwanese.\n* Histopathological confirmation of rectal adenocarcinoma.\n* Undergoing radical rectal resection or such surgery combined with temporary stoma closure.\n\nExclusion Criteria:\n\n* Diagnosis of other intestinal disorders, including intestinal tumors, bloating, obstruction, ulcerative colitis, or irritable bowel syndrome.\n* Inability to access the internet.\n* Inability to use a smartphone.",{"count":56,"type":21},[24],"Patients with rectal cancer complicated by low anterior resection syndrome who undergo anal-preserving surgery may experience severe distress in daily life due to changes in bowel function, thus requiring significant post-discharge care support from healthcare professionals. This study is a multicenter, non-blinded randomized controlled trial. One hundred patients with rectal cancer complicated by low anterior resection syndrome are planned to be randomly assigned in a 1:1 ratio from the colorectal surgery outpatient clinics of National Taiwan University Hospital, its Cancer Center, and its Yunlin Branch. They will be divided into a control group receiving routine dietary education and an experimental group receiving both routine dietary education and the use of an artificial intelligence-based dietary care system application. The artificial intelligence-based dietary care system application will be used for approximately six months. Three questionnaires will be administered at one month post-surgery (before intervention), three months post-surgery, and six months post-surgery. The questionnaires will include: a demographic data sheet, a low anterior resection syndrome score, distress inventory from altered bowel functioning, and the European Organization for Research and Treatment of Cancer QLQ-30 Scale, to verify the effectiveness of the artificial intelligence-based dietary care system application in improving bowel disturbance and quality of life in patients with rectal cancer complicated by low anterior resection syndrome.",[442],"AI Care Device","2026-06-03",{"date":322,"type":37},{"date":39,"type":21},{"date":69,"type":21},{"name":43,"class":44},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":455,"minAge":139,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":471,"leadSponsor":472,"locationsCount":45},"100640868","phase-1-exploring-auger-enhanced-psma-targeted-radioligand-therapy-a-first-in-taiwan-clinical-study-of-161tb-psma-it-100640868","NCT07621692","Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T","Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T in Patients With Metastatic Castration-Resistant Prostate Cancer","Inclusion Criteria:\n\n1. Age ≥ 20 years, ability to understand and willingness to sign informed consent, cooperate with all study-related procedures and assessments including blood tests and imaging\n2. Histologically confirmed adenocarcinoma of the prostate with evidence of metastatic castration-resistant prostate cancer (mCRPC)\n3. Prior surgical orchiectomy or chemical castration maintained on luteinizing hormone-releasing hormone analog, with a serum testosterone level \\\u003C50 ng\u002FdL (castrate range)\n4. Prior treated with at least one line of taxane-based chemotherapy unless medically unsuitable, and at least one line of androgen receptor pathway inhibitor (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide)\n5. Prior treated with 177Lu-labeled PSMA RLT unless medically unsuitable or declined by the patient\n6. Progressive disease defined according to Prostate Cancer Clinical Trials Working Group 3: Either a PSA progression of more than 2 rising PSA values from baseline with intervals ≥ 1 week, or a soft-tissue progression on images per RECIST 1.1 criteria, or a bone progression on images with more than 2 new lesions\n7. Evidence of significant PSMA-avid lesions on 68Ga- or 18F-labeled PSMA PET\u002FCT within 12 weeks prior to screening, which defined as 68Ga-PSMA or 18F-PSMA uptake greater than that of liver or spleen parenchyma (depend on the tracer used) in at least one metastatic lesion of any size in any organ system\n8. A life expectancy of ≥ 6 months and Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n9. Adequate bone marrow and organ functions 9.1 Hemoglobin ≥ 10 g\u002FdL without RBC transfusion within 4 weeks 9.2 Absolute neutrophil count ≥ 1.5 × 109\u002FL 9.3 Platelet count ≥ 150 × 109\u002FL 9.4 Creatinine clearance ≥ 50 mL\u002Fmin (Cockcroft-Gault) 9.5 AST and ALT ≤ 3 × ULN, total bilirubin ≤ 1.5 × ULN\n10. Willingness to comply with the use of medically acceptable forms of barrier contraception if sexually active\n\nExclusion Criteria:\n\n1. History of allergic reaction to PSMA-targeted compounds or radiometals\n2. Prior radioligand therapy with 223Ra or 177Lu-PSMA within 6 months\n3. Prior surgery or radiotherapy within 4 weeks prior to first investigational dose\n4. Prior systemic therapies against prostate cancer within 4 weeks, including androgen receptor pathway inhibitor, chemotherapy, targeted therapy such as PARP inhibitors (PARPi)\n5. Discordant disease on PET images: FDG-positive disease with minimal PSMA expression\n6. Urinary tract obstruction causing hydronephrosis unless appropriately treated beforehand\n7. Known symptomatic brain metastases or leptomeningeal disease, symptomatic or impending cord compression unless appropriately treated beforehand\n8. Other active malignancy requiring systemic treatment\n9. Significant cardiovascular disease (e.g., recent myocardial infarction, unstable angina)\n10. Concurrent severe uncontrolled illness that may jeopardize patient safety, including uncontrolled infections","MALE",{"count":457,"type":21},12,[459],"PHASE1","This study is a phase I dose escalation clinical trial aims to evaluate 161Tb-PSMA-I\\&T, a new generation prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) using Terbium-161 to replace Lutetium-177, its safety, dosimetry, biodistribution, pharmacokinetics, and preliminary efficacy in Taiwanese men with metastatic castration-resistant prostate cancer, and to inform future clinical trials.",[462],"Metastatic Castration Resistant Prostate Cancer (mCRPC)",[464,465,466,462],"Radioligand therapy","Terbium-161","Prostate-specific Membrane Antigen (PSMA)","2026-05-29",{"date":469,"type":37},"2026-06-02",{"date":390,"type":37},{"date":97,"type":21},{"name":43,"class":44},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":486,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":4},"100639002","comparison-of-the-diagnostic-accuracy-between-three-dimensional-and-standard-colonoscopy-of-colorectal-polyps-100639002","NCT07619248","Comparison of the Diagnostic Accuracy Between Three Dimensional and Standard Colonoscopy of Colorectal Polyps","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Patients who meet the indications for undergoing colonoscopy.\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age or those with contraindications precluding them from undergoing a colonoscopy.\n\n(Contraindications for colonoscopy: patients with a recent history of myocardial infarction, pulmonary embolism, cerebrovascular infarction, severe unstable cardiovascular disease, acute abdominal inflammation combined with peritonitis, fulminant colitis, acute diverticulitis, colonic perforation, or toxic megacolon).\n\n* Patients with familial hereditary colorectal cancer or colonic polyposis syndromes.\n* Patients with inflammatory bowel disease (IBD).\n* Subjects who are unable to complete the colonoscopy or those with poor bowel preparation.\n* Subjects who are unable to confirm the date of their previous colonoscopy.",{"count":480,"type":21},600,[24],"Colorectal cancer (CRC) is one of the most common cancers worldwide. These malignancies originate in the colon or rectum, and the majority evolve from pre-existing colonic adenomas (a type of colon polyp). Early detection, identification, and removal of these precancerous lesions can effectively reduce the morbidity and mortality of colorectal cancer.\n\nHowever, not all colonic polyps possess a significant risk of malignant transformation. Polyps can generally be subdivided into \"neoplastic\" and \"non-neoplastic\" lesions; major non-neoplastic polyps include inflammatory polyps, hamartomas, lymphoid polyps, mucosal prolapse polyps, and hyperplastic polyps. On the other hand, neoplastic polyps have the potential to develop into malignancies, primarily including adenomatous polyps and serrated polyps. Adenomatous polyps account for more than 50% of all colonic polyps and are the most common precancerous lesions for CRC. Clinically, they can be further classified into tubular, tubulovillous, or villous adenomas based on histological subtypes. As for serrated polyps, traditional serrated adenomas (TSAs) and sessile serrated lesions (SSLs) possess carcinogenic potential.\n\nDuring a colonoscopy, detecting colonic polyps is crucial, but it is equally important to identify which polyps have malignant potential. This allows for the accurate resection of true precancerous lesions while avoiding the procedural risks associated with unnecessary polypectomies. Furthermore, in rare instances, diminutive polyps may harbor cancer with deep submucosal invasion. Due to the risks of incomplete resection and lymph node metastasis, such lesions are not suitable for endoscopic resection. Therefore, achieving an accurate endoscopic diagnosis is a key step in determining the most appropriate management strategy for colonic polyps.\n\nTo improve the diagnostic accuracy of endoscopy for colonic polyps, multiple modalities have been developed, including careful observation of lesion morphology, as well as various image-enhanced technologies and chromoendoscopy. Meanwhile, three-dimensional (3D) endoscopy, a novel technology, offers superior spatial resolution and depth perception compared to conventional two-dimensional (2D) endoscopy. Studies have confirmed that 3D endoscopy can improve the adenoma detection rate (ADR) due to its enhanced ability to detect flat and inconspicuous lesions. However, whether 3D colonoscopy can also enhance the endoscopic diagnostic accuracy for colonic polyps remains to be explored. Therefore, we designed a randomized controlled trial (RCT) to investigate whether 3D colonoscopy can improve the diagnostic accuracy of colonic polyps compared to conventional 2D colonoscopy.",[484,485],"Colo-rectal Polyps","Colonoscopy",[487,485,488,489],"Endoscopy","Colo-rectal polyps","3D Endoscopy","2026-05-28",{"date":492,"type":37},"2026-06-01",{"date":494,"type":21},"2026-05-12",{"date":496,"type":21},"2027-05-12",{"name":43,"class":44},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":506,"conditions":507,"keywords":511,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":525,"leadSponsor":526,"locationsCount":71},"100638268","ai-based-wound-monitoring-automated-wound-progression-assessment-via-marker-free-image-sequence-100638268","NCT07619430","AI-Based Wound Monitoring: Automated Wound Progression Assessment Via Marker-Free Image Sequence","Inclusion Criteria:\n\n* (1) Presence of a hard-to-heal wound that has remained unhealed for more than one month. (2)The wound can be photographed according to the standardized imaging protocol. (3)The participant was aged 18 years or older and provided informed consent personally or via a legally authorized representative, with a signed informed consent form.\n\nExclusion Criteria:\n\n* Wounds whose margins could not be fully included within the imaging field.",{"count":505,"type":21},1000,"This study aims to develop a low-cost, marker-free intelligent wound assessment system that can analyze wound photos taken with a standard smartphone. By comparing wound images over time, the system will generate a quantifiable Wound Progression Index (WPI) to provide objective feedback on whether a wound is improving, stable, or worsening. The long-term goal is to support early detection of wound deterioration and improve wound care in both clinical and home settings.",[508,341,509,510],"Hard-to-heal Wounds","Wound Care","Pressure Injuries",[512,513,514,515,516,517,518,519,520,521],"chronic wounds","wound assessment","medical AI","semantic segmentation","longitudinal image registration","marker-free","wound progression index","home-based care","telemedicine","clinical validation","2026-05-27",{"date":469,"type":37},{"date":350,"type":21},{"date":174,"type":21},{"name":43,"class":44},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":54,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":22,"phases":535,"briefSummary":536,"conditions":537,"keywords":541,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":552,"locationsCount":71},"100638984","virtual-forest-based-mindfulness-for-perinatal-mental-health-100638984","NCT07606248","Virtual Forest-Based Mindfulness for Perinatal Mental Health","Evaluating the Effects of an Integrated Virtual Forest Environment and Mindfulness-Based Intervention on Mental Health in Perinatal Women","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* Gestational age below 25 weeks at recruitment\n* Able to communicate in Chinese and provide informed consent\n* Willing to participate in the study and complete follow-up assessments\n\nExclusion Criteria:\n\n* Diagnosed epilepsy, photosensitive epilepsy, or other neurological disorders\n* Severe anxiety, depression, or other psychiatric disorders currently receiving intensive treatment\n* History of severe adverse reactions to virtual reality devices, including severe dizziness, nausea, or visual discomfort\n* Inability to participate in mindfulness or VR intervention proceduresriteria:\n\nExclusion Criteria:\n\n\\-",{"count":56,"type":21},[24],"Perinatal anxiety and depression are common mental health concerns that may negatively affect maternal well-being, infant development, and family functioning. Mindfulness-based interventions have shown beneficial effects on reducing psychological distress during pregnancy; however, maintaining attention and engagement during mindfulness practice may be challenging for some pregnant women.\n\nThis randomized controlled trial aims to evaluate the feasibility and effectiveness of an integrated virtual forest environment and mindfulness-based intervention for improving mental health in perinatal women. Pregnant women between 20 and 24 weeks of gestation will be randomly assigned to either an experimental group receiving virtual reality (VR)-based forest mindfulness intervention or a control group receiving conventional mindfulness intervention.\n\nBoth groups will participate in a 9-week mindfulness program and receive app-based mindfulness practice. The experimental group will additionally receive immersive VR forest-based mindfulness sessions during prenatal visits. Outcomes including anxiety, depression, mindfulness awareness, physiological indicators, and intervention acceptability will be assessed during pregnancy and postpartum follow-up.",[538,539,540],"Perinatal Anxiety","Perinatal Depression","Maternal Mental Health",[542,543,544,545,546],"Virtual reality","Mindfulness","Forest therapy","Perinatal mental health","Pregnancy","2026-05-26",{"date":467,"type":37},{"date":550,"type":21},"2026-05-25",{"date":174,"type":21},{"name":43,"class":44},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":54,"sex":17,"minAge":560,"maxAge":4,"enrollmentInfo":561,"targetDuration":563,"studyType":82,"phases":4,"briefSummary":564,"conditions":565,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":4},"100637944","ai-based-risk-prediction-model-for-upper-digestive-tract-cancer-100637944","NCT07605312","AI-Based Risk Prediction Model for Upper Digestive Tract Cancer","Development of Artificial Intelligence Risk Prediction Model for Upper Digestive Tract Cancer Using High Resolution Endoscopic Image, Digital Pathology, Genetics, and Oro-gastro-intestinal Microbiota.","Inclusion Criteria:\n\n* Patients undergoing upper gastrointestinal endoscopy.\n* Patients with at least one of the following conditions or indications:\n\n  * Previous or current Helicobacter pylori infection (confirmed by serology, histopathology, urea breath test, rapid urease test, or stool antigen test);\n  * Dyspeptic symptoms;\n  * Gastroesophageal reflux disease;\n  * History of oral, oropharyngeal, or hypopharyngeal squamous cell carcinoma;\n  * Barrett's esophagus;\n  * Gastric premalignant lesions (intestinal metaplasia or atrophic gastritis);\n  * Gastric subepithelial lesions.\n\nExclusion Criteria:\n\n\\-","40 Years",{"count":562,"type":21},10000,"10 Years","Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development. This prospective multicenter cohort study aims to establish a longitudinal database integrating clinical information, endoscopic findings, pathology, genetics, epigenetics, and gastrointestinal microbiota data from subjects undergoing upper digestive tract endoscopy.\n\nThe study will develop explainable artificial intelligence (AI)-based risk prediction models to identify factors associated with disease progression, treatment response, and cancer development. Participants will be followed longitudinally to evaluate changes in lesion severity and clinical outcomes.",[566,146,567,568,569,570],"Gastric Cancer (GC)","Gastric Intestinal Metaplasia","Atrophic Gastritis","Dysplasia Stomach","Esophageal Cancer (EsC)",{"date":490,"type":37},{"date":573,"type":21},"2026-05-18",{"date":575,"type":21},"2030-05-18",{"name":43,"class":44},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":139,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":22,"phases":587,"briefSummary":581,"conditions":588,"keywords":591,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":71},"100638714","improving-outcomes-after-af-ablation-in-obese-patients-100638714","NCT07618741","Improving Outcomes After AF Ablation in Obese Patients","Outcome Improvement in Obese Patients With Atrial Fibrillation After Catheter Ablation: Importance of Gut Microbiota Dysbiosis and Adipose Tissue Biology","OBESE-AF","Inclusion Criteria:\n\n* Patients with Class I indication of catheter ablation of paroxysmal or persistent AF and will undergo catheter ablation at National Taiwan University Hospital.\n\nExclusion Criteria:\n\n1. Informed consent could not be obtained due to personal problem\n2. Unwillingness or inability to return for follow-up visits or reason to believe that adherence to follow-up visits wound be irregular\n3. Current or scheduled enrollment in other conflicting studies, and\n4. Concomitant disease or other medical condition likely to result in death within 6 months",{"count":586,"type":21},520,[24],[589,590],"Atrial Fibrillation (AF)","Obesity (Disorder)",[315,316,592,593,594,595,596,597],"Obesity","Gut microbiota dysbiosis","Epicardial adipose tissue","Cardiac rehabilitation","Lifestyle modification","Left atrial remodeling","2026-05-24",{"date":492,"type":37},{"date":601,"type":37},"2021-09-16",{"date":603,"type":21},"2030-05",{"name":43,"class":44},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":139,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":614,"briefSummary":617,"conditions":618,"keywords":620,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":4},"100637774","phase-2-colchicine-for-the-prevention-of-post-operative-atrial-fibrillation-after-coronary-artery-bypass-grafting-a-single-center-strategy-stratified-randomized-double-blind-placebo-controlled-trial-100637774","NCT07611019","Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial","Randomized, Double-Blind, Placebo-Controlled Trial of Colchicine to Prevent Post-Operative Atrial Fibrillation After CABG With Strategy-Stratified Randomization","Inclusion Criteria:\n\n* Adults aged 20 years or older scheduled to undergo elective coronary artery bypass grafting (CABG), including either off-pump CABG or on-pump CABG.\n* Ability to receive oral study medication before and after surgery.\n* Provision of written informed consent before randomization.\n\nExclusion Criteria:\n\n* History of atrial fibrillation or atrial flutter before surgery.\n* Severe renal impairment (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²) or chronic dialysis.\n* Severe hepatic dysfunction.\n* Known hypersensitivity or previous severe adverse reaction to colchicine.\n* Pregnancy or breastfeeding.\n* Current use of strong CYP3A4 or P-glycoprotein inhibitors that cannot be safely discontinued or substituted.\n* Any condition judged by the investigators to interfere with study participation or safety assessment.",{"count":613,"type":21},400,[615,616],"PHASE2","PHASE3","Post-operative atrial fibrillation after coronary artery bypass grafting (CABG)",[619],"Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG)",[621,622,623,624,625,626,627,628],"colchicine","postoperative atrial fibrillation","coronary artery bypass grafting","off-pump surgery","cardiopulmonary bypass","pharmacokinetics","inflammation","neutrophil extracellular traps","2026-05-20",{"date":490,"type":37},{"date":632,"type":21},"2026-06",{"date":634,"type":21},"2028-07",{"name":43,"class":44},""]